PBPaxton Bach

Paxton Bach

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Paxton Bach has a total of 248 co-authors. Here are the top co-authors by number of shared publications:

  • Kanna Hayashi

    British Columbia Centre on Substance Use, Vancouver, Canada; Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada

    7 shared publications
  • Nadia Fairbairn

    British Columbia Centre on Substance Use, Vancouver, BC, Canada; Division of Social Medicine, Department of Medicine, University of British Columbia, Vancouver, BC, Canada

    6 shared publications
  • Thomas Kerr

    Department of Medicine, University of British Columbia, Vancouver, BC, Canada

    6 shared publications
  • Evan Wood

    BC Centre on Substance Use Vancouver Canada

    5 shared publications
  • Evan Wood

    University of British Columbia

    5 shared publications
  • Kanna Hayashi

    British Columbia Centre on Substance Use, Suite 400-1045 Howe Street, Vancouver, BC V6Z 2A9, Canada; Faculty of Health Sciences, Simon Fraser University, 8888 University Drive, Burnaby, BC V5A 1S6, Canada

    5 shared publications

Latest Publications

  • Safety and effectiveness of rapid methadone titration protocols in opioid use disorder: A systematic review

    by Jean Zhuo Wang, Brittany Dennis, Ashish P. Thakrar, Sukhpreet Klaire, Paxton Bach

    Background and aims: Methadone is an effective, first‐line treatment for opioid use disorder. Guidelines recommend slow titration to minimize the risk of methadone toxicity, a process exposing patients to sub‐therapeutic doses for weeks to months. Protocols that titrate more rapidly reduce the time to achieving a therapeutic dose. This systematic review evaluated the safety and effectiveness of rapid methadone titrations in patients with opioid use disorder. Method: Systematic review of prospective and retrospective studies of patients undergoing rapid methadone titration for treatment of opioid use disorder. Both outpatient and inpatient/acute settings were included. Results: A total of 4297 records were screened from MEDLINE, EMBASE, Cochrane CENTRAL and PsycINFO. Following the initial screen, 79 texts were reviewed in full, with 29 studies included in the review, representing 16 154 participants. A wide variety of rapid titration schedules were described across inpatient and outpatient settings. A common protocol (6 studies) started at 30–40 mg, with additional 10 mg every 3–4 hours as needed up to 50–80 mg on day 1. Average dose on day 7 ranged from 53 to 97 mg across 5 randomised controlled trials/cohort studies ( n = 14 758) and from 60 to 200 mg in 5 case series/case reports ( n = 124). Among 26 studies reporting on mortality ( n = 1431), there were 63 deaths in 3 outpatient studies over 2–180 days after starting methadone; 61 deaths were from 2 case series that specifically selected cases of death from coroner reports. Among all 18 studies conducted in the fentanyl era (post‐2013, n = 705), and all 18 inpatient studies from any time period ( n  = 604) reporting on mortality, there were no deaths reported. Overdose rates were less than 1% across all studies and sedation events were often mild, with most patients continuing methadone. One study found a correlation between improved retention rates and higher methadone doses during the first week of initiation. Pooled analysis could not be performed due to substantial heterogeneity across studies. Summary: A wide range of rapid methadone titration protocols for opioid use disorder are described in the literature, with generally low‐quality evidence and little standardization in protocols or evaluations. Overall adverse events were rare, particularly with rapid methadone titration in the fentanyl era and during inpatient admissions. Data on retention in treatment and changes in unregulated drug use were limited.

  • Open Access

    Prescribed alternative stimulants among people who use unregulated stimulants: Examining the association between maximum dose reached and medication discontinuation in the first 3 years of implementation in British Columbia, Canada

    by Bin Zhao, Kevin Hu, Roshni Desai, Shania Au, Kali‐Olt Sedgemore, Vitor Tardelli, Addie Carter, Paxton Bach, Christian Schutz, Amanda Slaunwhite, et al.

    Background and aims: In 2020, British Columbia (BC), Canada, introduced ‘Prescribed Alternatives’ (PA) as an approach to offering regulated substances to people accessing the unregulated supply. This study aimed to estimate and compare prescribing characteristics of dextroamphetamine and methylphenidate stimulant PAs in BC, to estimate medication discontinuation probabilities for each PA type by episode order, and to estimate the hazard ratio for medication discontinuation comparing episodes that reached a maximum daily stimulant PA dose of ≥60 mg/day with episodes that did not. Design: Population‐based retrospective cohort study using linked provincial administrative health data. The analysis included people who were identified to have received a stimulant PA prescription between 27 March 2020 (the day after guidance for prescribing PAs was released in BC) and 31 July 2023. The study was reported in accordance with the STROBE guideline. Setting: BC, Canada (27 March 2020–31 July 2023). Participants: People who received stimulant PA prescriptions during the study period in BC. These were people who use unregulated stimulants and who, in the judgement of their prescriber, might benefit from prescribed psychostimulants from either a treatment or harm reduction perspective. A total of 1683 people (35.6% female) contributed 4842 stimulant PA medication episodes (dextroamphetamine or methylphenidate) to the study. Measurements: The primary outcome was time to medication discontinuation within each stimulant PA episode. The primary exposure was reaching a daily dose of ≥60 mg. Prentice, Williams and Peterson's Gap Time survival models were used to estimate adjusted hazard ratios for discontinuation by dose, adjusting for demographic (sex, age, health authority) and clinical covariates [stimulant prescription history, opioid agonist treatment (OAT) prescription history and concurrent OAT prescription during episodes]. Findings: Most episodes remained at the initial dispensed dose, with only 25.8% of dextroamphetamine and 38.4% of methylphenidate episodes reaching ≥60 mg/day. Episodes that did not reach this threshold had a higher hazard of discontinuation compared with those that did [hazard ratio (HR) = 1.21; 95% confidence interval (CI) = 1.11–1.32 for dextroamphetamine; HR = 1.12; 95% CI = 1.00–1.25 for methylphenidate]. While robust dosing was associated with improved retention, discontinuation remained high overall, and stimulant PA uptake was low relative to estimated eligibility. Conclusions: Doses of stimulant prescribed alternatives (dextroamphetamine and methylphenidate) that reach 60 mg or more per day appear to be associated with longer treatment episodes than lower doses. Discontinuation is high across both medications. Concurrent opioid agonist treatment appears to be associated with a lower hazard of discontinuation. Dosing alone is unlikely to sustain long‐term engagement for all patients.

  • Open Access

    Real‐world comparative effects of slow‐release oral morphine vs. methadone on healthcare use for opioid use disorder: A population‐based target trial emulation

    by Vivienne Y. Zhou, Nadia Fairbairn, Jingxin Lei, Rupinder Brar, Paxton Bach, M. Eugenia Socias

    Aims: To examine the comparative effects of slow‐release oral morphine (SROM) vs. methadone for the treatment of opioid use disorder (OUD) on healthcare use. Design: This retrospective cohort study emulated a target trial using electronic medical record data from Vancouver Coastal Health Authority linked with population‐based administrative health data from British Columbia (BC), Canada. Setting: Vancouver Coastal Health region in BC, between 1 July 2017 and 30 June 2024, operating under a universal healthcare system, where the majority of illicit opioids are contaminated with fentanyl. Participants: OUD patients aged between 18 and 65 years. Interventions: Intent‐to‐treat (ITT): receiving a new prescription of SROM or methadone for the treatment of OUD (regardless of treatment initiation or adherence). Per‐protocol (PP): initiating and adhering to the prescribed SROM vs methadone (real‐world on‐treatment exposure). Measurements: The daily rate of healthcare use—including all‐cause and opioid‐specific emergency department (ED) visits, all‐cause and opioid‐specific hospitalization days, all‐cause physician encounters/services, OUD‐related physician visits, and non‐OUD‐related primary care physician visits—over 1 year following treatment prescription or initiation was modelled using weighted modified Poisson regression with generalized estimating equations. Cumulative healthcare use at 1 year and corresponding adjusted rate ratios (aRRs) were estimated. Findings: We identified 3254 unique individuals [median (Q1–Q3) age 37 (30–46) years, 64.2% male] contributing to 4059 person‐trials (eligible treatment episodes) for the ITT analysis (32.6% SROM) and 1992 unique individuals contributing to 2276 person‐trials for the PP analysis (27.4% SROM). ITT analysis shows that receiving a SROM vs. methadone prescription was not associated with statistically significant differences in the rates of all‐cause [aRR = 1.10, 95% confidence interval (CI) = 0.997–1.20] and opioid‐specific ED visits (aRR = 1.00, 95% CI = 0.90–1.13), all‐cause (aRR = 0.99, 95% CI = 0.81–1.18) and opioid‐specific hospitalization days (aRR = 0.97, 95% CI = 0.78–1.20), all‐cause physician encounters/services (aRR = 1.00, 95% CI = 0.94–1.06), OUD‐related physician visits (aRR = 0.94, 95% CI = 0.87–1.01) and primary care physician visits (aRR = 1.11, 95% CI = 0.98–1.24). PP analysis also did not observe statistically significant differences across healthcare outcomes among those who initiated and remained on SROM vs. methadone treatment, with aRRs of 1.24 (95% CI = 0.91–1.50), 1.01 (95% CI = 0.67–1.36), 1.06 (95% CI = 0.65–1.58), 0.95 (95% CI = 0.53–1.58), 1.03 (95% CI = 0.90–1.17), 0.97 (95% CI = 0.82–1.14) and 1.06 (95% CI = 0.73–1.46), respectively. Conclusions: This emulated trial on opioid use disorder patients under a universal healthcare setting in Canada did not observe statistically significant differences in risk of healthcare use outcomes between the patients receiving slow‐release oral morphine and those receiving methadone following treatment prescription and initiation. This supports slow‐release oral morphine as a viable alternative to methadone with similar real‐world effectiveness in preventing all‐cause and opioid‐related acute healthcare needs and the potential to expand treatment options for opioid use disorder without increasing health system burden.

  • Open Access

    Comparative effectiveness of alternative times to opioid agonist treatment taper initiation on taper completion and all‐cause mortality among people with opioid use disorder: A retrospective population‐based target trial emulation study in British Columbia, Canada, 2010–2020

    by Ruyu Yan, Jeong Eun Min, Megan Kurz, Shaun R. Seaman, Paxton Bach, Sander Greenland, Paul Gustafson, Mohammad Ehsanul Karim, Lawrence McCandless, Robert William Platt, et al.

    Background and aims: Opioid use disorder (OUD) treatment guidelines worldwide recommend opioid agonist treatment (OAT) as a long‐term, potentially indefinite treatment for managing OUD. However, many individuals express a strong interest in eventually tapering fully off treatment. Current clinical practice guidelines offer relatively limited guidance or evidence on the appropriate timing to initiate a taper. We aimed to determine the safety and comparative effectiveness of different times from completion of OAT induction at which tapering could be considered to maximize the likelihood of taper completion and minimize the risk of mortality. Design: Population‐based retrospective observational study and target trial emulation based on nine linked administrative health databases. Setting: British Columbia, Canada, from 1 January 2010 to 17 March 2020. Participants: Individuals (identified via linkage of nine provincial health administrative databases) completing OAT induction with methadone or buprenorphine/naloxone who were ≥18 years of age with no known pregnancy, no history of cancer or palliative care and not currently incarcerated. We executed both incident‐user (no OAT experiences) and prevalent‐new‐user (no OAT within the past month) analyses. Intervention and comparator: The time between completed OAT induction and taper initiation: <3 months, 3–6 months, 6–12 months, compared with 12–48 months. Measurements: The primary outcomes were completed taper (reaching a final daily dose of ≤5 mg/day for methadone, or ≤2 mg/0.5 mg/day for buprenorphine/naloxone) and all‐cause mortality. A clone‐censor‐weight approach was used to adjust for informative censoring and balance baseline characteristics between the groups. Logistic regression and pooled logistic regression models were used to estimate odds ratios (ORs) for completed taper and hazard ratios (HRs) for all‐cause mortality, respectively, each with 95% compatibility (‘confidence’) intervals. Findings: We included 17 726 incident users (buprenorphine/naloxone: 36.9%) and 49 515 treatment episodes (buprenorphine/naloxone: 31.2%) from 31 231 prevalent new users who completed induction in the analyses. Among prevalent new users, beginning tapering within 3 months, between 3 and 6 months and between 6 and 12 months of completing induction was associated with an increased likelihood of completed taper [methadone: <3 months: adjusted odds ratio (aOR) = 3.09, 95% compatibility interval (95% CI) = 2.58–3.68; buprenorphine/naloxone: <3 months: aOR = 6.90, 95% CI = 5.19–9.16] but a higher risk of mortality [methadone: <3 months: adjusted hazard ratio (aHR) = 1.18, 95% CI = 1.12–1.25; buprenorphine/naloxone: <3 months: aHR = 1.12, 95% CI = 1.05–1.19], compared with initiating a taper between 12 and 48 months. Similar results were found among incident users. Conclusions: Although initiating early tapering off opioid agonist treatment may be associated with a greater likelihood of taper completion, this practice also increases the risk of mortality.

  • Open Access

    Uptake and Retention on Prescribed Psychostimulants for Harm Reduction: A Canadian Cohort Study

    by Paxton Bach, JinCheol Choi, Wing Yin Mok, M-J Milloy, Kora DeBeck, Thomas Kerr, Kanna Hayashi

    Background: Methamphetamine use is on the rise in North America and is a growing contributor to the ongoing overdose crisis. Prescription psychostimulants have been available for patients with stimulant use disorder through a provincial harm reduction policy in British Columbia, Canada, since 2020, however, there is little data to inform the uptake of and retention in this intervention in the real-world. Methods: Data from 3 harmonised prospective cohorts of people who use drugs in Vancouver, Canada, were examined for information on uptake, prescribing patterns, and retention on prescribed psychostimulants provided for the purposes of harm reduction among people who use non-prescribed stimulants. We used a general estimating equations model to examine factors associated with their use. Results: Among 1005 participants interviewed between 2020 and 2022, 79 (7.9%) received at least one prescription for a psychostimulant as a harm reduction intervention. Daily methamphetamine use and being engaged in some form of addiction treatment were both associated with increased odds of receiving a prescription while later calendar year and age were associated with decreased odds (all P < .05). Dextroamphetamine was the most common prescription (70%), followed by methylphenidate (29%). Retention on prescribed psychostimulants was low with only 23% of those receiving a prescription still on the medication at 6-month follow-up. Conclusion: We observed a low and declining uptake of psychostimulant prescriptions provided for harm reduction purposes during this period, along with poor retention in treatment. These results suggest that further research should investigate factors to improve uptake and engagement of this medication among people who use stimulants, including patient suitability and dosing patterns.

  • Open Access

    Effectiveness of slow-release oral morphine versus other OAT regimens in key sub-populations: protocol for population-based target trial emulation

    by Momenul Haque Mondol, Jeong Eun Min, Michelle Zanette, Maria Eugenia Socías, Paul Gustafson, Paxton Bach, Robert William Platt, Shaun Seaman, Sander Greenland, Bohdan Nosyk

    Introduction: Slow-release oral morphine (SROM) was introduced as an alternative form of opioid agonist treatment (OAT) in British Columbia (BC), Canada in 2017. While clinical guidelines in BC recommend SROM based on expert consensus and experience, there is limited real-world evidence on populations most likely to benefit from SROM compared to other forms of OAT, particularly in the context of widespread fentanyl exposure. We will estimate the comparative effectiveness of SROM versus methadone and buprenorphine/naloxone on OAT discontinuation and all-cause mortality among key sub-populations in BC. Methods: We will conduct a population-level retrospective cohort study using linked data from nine provincial health administrative databases. The study population includes adults (≥18 years) in BC who initiated SROM, methadone, or buprenorphine/naloxone between June 1, 2017, and December 31, 2022. Key sub-populations will include incident users with no prior OAT history and prevalent new users with prior OAT experience stratified by OAT type, stability, and medication switching history. The primary outcomes are time to OAT discontinuation and all-cause mortality, while overdose-related acute care visits will be examined as a secondary outcome. To estimate both the initiator effect and the effect of treatment at guideline-recommended doses, we will apply marginal structural models using inverse probability treatment weighting and ‘clone-censor-weights’ approach to address confounding by indication and time-varying confounding. Sensitivity analyses will evaluate the robustness of our findings, including cohort and timeline restrictions, alternative outcome definitions, and alternative estimation strategies including high-dimensional propensity score and instrumental variable approaches. Discussion: This study will generate real-world evidence on the comparative effectiveness of SROM versus methadone and buprenorphine/naloxone across clinically distinct OAT sub-populations. The findings will support evidence-informed updates to OAT guidelines and clinical decision-making in BC and other jurisdictions facing escalating opioid-related harms.

  • Open Access

    Comparative effectiveness of urine drug testing schedules alongside opioid agonist treatment: Emulation of a population‐based target trial in British Columbia, Canada

    by Megan Kurz, Brenda Carolina Guerra‐Alejos, Jeong Eun Min, Shaun R. Seaman, Micah Piske, Paxton Bach, Julie Bruneau, Sander Greenland, Paul Gustafson, Kyle Kampman, et al.

    Background and aim: Urine drug testing is often utilized alongside opioid agonist treatment to assess client progress by validating self‐reported substance use, monitoring for diversion and supporting clinical decisions for take‐home dosing. However, there is a paucity of evidence to support the practice of urine drug testing. We aimed to determine the association of alternative urine drug testing frequencies with opioid agonist treatment discontinuation, compared with no monitoring, among individuals receiving methadone or buprenorphine/naloxone treatment. Design: Population‐based retrospective cohort study and target trial emulation based on nine‐linked administrative databases. Setting: British Columbia, Canada, between 1 January 2010 and 17 March 2020. Participants: Individuals with no history of cancer or palliative care, aged 18 or older and no indication of pregnancy who initiated methadone or buprenorphine/naloxone. A total of 18 988 methadone and 11 910 buprenorphine/naloxone recipients were included in the incident user design (individuals with no past opioid agonist treatment experience). Measurements: We used a clone‐censor‐weight approach to estimate hazard ratios with 95% compatibility (“confidence”) intervals for treatment discontinuation (lasting at least 5 and 6 days for methadone and buprenorphine, respectively) and all‐cause mortality on treatment within 12 months for static urine drug testing strategies. Findings: Under static monitoring strategies, weekly urine drug testing was associated with a slightly reduced risk of discontinuation in the first year of continuous retention in treatment [methadone: adjusted hazard ratio (aHR) = 0.96, 95% compatibility interval (CI) = (0.95–0.98); buprenorphine/naloxone: aHR = 0.95 (0.94–0.97)] compared with no monitoring. The estimated associations of weekly urine drug testing with all‐cause mortality were similar in size but extremely imprecise [methadone: aHR = 0.95 (0.78–1.15), buprenorphine/naloxone: aHR = 0.99 (0.62–1.58)]. Less frequent testing demonstrated no observed difference on treatment discontinuation or all‐cause mortality compared with no monitoring. Conclusion: Compared with no urine drug testing, weekly urine drug testing may be associated with improved opioid agonist treatment retention; however, the high costs attributable to frequent testing may not be cost‐effective and requires further evaluation. There was no improvement associated with less frequent testing compared with no monitoring.


  • Open Access

    Impact of hepatitis C serostatus on health service utilization for opioid-related harms among individuals prescribed opioid agonist therapy: A longitudinal prospective cohort study

    by Paige Guyatt, Glenda Babe, Anastasia Gayowsky, Tea Rosic, Myanca Rodrigues, Paxton Bach, Richard Perez, Claire de Oliveira, Jeffrey H. Samet, Geneviève Kerkerian, et al.


  • Trends in stimulant use among patients with opioid use disorder receiving substance use treatment: Findings from a prospective cohort study from 2013 to 2020

    by Elise Jackson, Paxton Bach, M. Eugenia Socias, Olivia M. Brooks, Nadia Fairbairn, Myanca Rodrigues, Tea Rosic, Leen Naji, Samara Jinks-Chang, Seonaid Nolan, et al.


  • Open Access

    Association between prescribed stimulant medications and overdose among individuals receiving opioid agonist therapy: A retrospective cohort study from British Columbia, Canada

    by Samantha Young, Nadia Fairbairn, Zishan Cui, Paxton Bach, Wing Yin Mok, Juls Budau, Amanda Slaunwhite, Lianping Ti, Kanna Hayashi, Seonaid Nolan

    Aims: We measured the association between prescribed stimulant medications and overdose among individuals receiving opioid agonist therapy (OAT) for opioid use disorder. Design: Retrospective cohort study using the British Columbia Provincial Overdose Cohort, a linked administrative database. Setting: We used data from British Columbia, Canada, from January 2015 through February 2020. Participants: In total, 9395 individuals contributed 18 273 person‐years of follow‐up while dispensed OAT. Measurements: We examined the association between stimulant prescription (primary exposure) and fatal or non‐fatal overdose (primary outcome, allowing for recurrent events) after adjusting for potential confounders including sociodemographic characteristics and substance use patterns. As a secondary analysis, we evaluated type of OAT (full agonists involving methadone or slow‐release oral morphine versus partial agonist involving buprenorphine/naloxone alone) as a potential effect modifier. Findings: There were 1746 overdose events; 37 (2.1%) were fatal. Overall, there was no increased risk of overdose among individuals dispensed a stimulant medication while on OAT [adjusted Cox regression hazard ratio (AHR) = 1.13, 95% confidence interval (95% CI) = 0.86–1.49, P = 0.39]. When analyzed by type of OAT medication, for individuals on buprenorphine, dispensation of a stimulant medication was associated with a reduced risk of overdose (AHR = 0.47, 95% CI = 0.23–0.96, P = 0.037) while, for individuals on full agonist OAT, dispensation of a stimulant medication was associated with an increased risk of overdose (AHR = 1.51, 95% CI = 1.09–2.07, P = 0.012). Conclusions: There does not appear to be an overall increased risk of overdose for individuals co‐prescribed a stimulant medication with opioid agonist therapy (OAT). There appears to be a reduced risk of overdose for individuals dispensed buprenorphine with a stimulant medication compared with those dispensed buprenorphine alone, and an increased risk of overdose for individuals dispensed full agonist OAT (methadone or slow‐release oral morphine) with a stimulant medication compared with those dispensed full agonist OAT alone.